Colon & Colorectal Cancer · Article 168

How Should Familial Adenomatous Polyposis Be Recognized and Managed?

Familial adenomatous polyposis requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Familial adenomatous polyposis clinical reference — Related free clinical resource: Images in Gastroenterology and Hepatology.

Familial adenomatous polyposis: practical clinical approach

This page focuses on Familial adenomatous polyposis with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Familial adenomatous polyposis

Clinical takeaway: For Familial adenomatous polyposis, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Familial adenomatous polyposis should be suspected with hundreds of colorectal adenomas, very high cumulative adenoma burden, a compatible family history or extracolonic features. APC germline testing confirms most classic cases. Management requires early and repeated colorectal surveillance, prophylactic colorectal surgery when endoscopic control is no longer safe, and lifelong surveillance of the retained rectum or pouch plus the duodenum and ampulla. First-degree relatives require genetic counseling and age-appropriate testing.

The phenotype can vary

Classic FAP produces hundreds to thousands of adenomas; attenuated FAP can present with fewer polyps and later cancer.

Surgery prevents colorectal cancer

Choice between colectomy with ileorectal anastomosis and proctocolectomy with IPAA depends on rectal burden, genotype, patient preference and ability to adhere to surveillance.

Upper-GI disease matters

Duodenal and ampullary adenomas become an important cancer risk after colorectal risk is controlled.

Practical clinical algorithm

1. Suspect FAP from adenoma burden and family history.

2. Refer for germline genetic testing/counseling.

3. Begin lower-GI surveillance early in at-risk relatives.

4. Plan prophylactic surgery when polyp burden cannot be controlled endoscopically.

5. Continue lifelong rectal/pouch and upper-GI surveillance.

Common mistakes to avoid

Stopping surveillance after colectomy.
Ignoring the duodenum/ampulla.
Assuming a negative family history excludes FAP.
Delaying surgery until cancer develops.
Failing to test relatives.

Trainee takeaway

FAP management is lifelong cancer prevention across multiple GI sites; colectomy removes one major risk but does not end surveillance.

Frequently asked questions

Is FAP always inherited from a parent?

No. De novo APC variants occur.

Does colectomy cure FAP?

It greatly reduces colorectal cancer risk but extracolonic and retained-rectal/pouch risks remain.

When should upper endoscopy begin?

Timing depends on guideline and genotype, commonly in young adulthood.

References

1. Thomson ABR. Practice Review in Gastroenterology. CAPstone Academic Publishers; 2014.

2. Thomson ABR. Endoscopy and Diagnostic Imaging. Part I. CAPstone Academic Publishers; 2012.

3. Syngal S, et al. ACG Clinical Guideline: Genetic Testing and Management of Hereditary GI Cancer Syndromes. Am J Gastroenterol. 2015;110:223-262.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions